Clinical Trials Browser

Interventional × Melanoma × resiquimod × Clear all

Melanoma, Neoplasms

NCT00960752 2021-08-13

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

Phase 2 Completed

47 enrolled 9 charts

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Phase 1/2 Completed

70 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

NCT00470379 2014-10-31

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Phase EARLY_PHASE1 Completed

30 enrolled

Dermatologic

Melanoma

Clinical Trials

MEL60

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery